Mtar Technologies Limited (MTARTECH)
Transcript
AI summary
- Q1 FY27 revenue INR360.7 Cr +130% y-y; EBITDA INR85.1 Cr margin 23.6%
- FY27 revenue growth guidance 80% with EBITDA margin ~24%, confident to exceed
- Nuclear segment order book ~INR800 Cr; execution 1-3 years; refurbishment orders ~INR200 Cr
- Clean Energy capacity expansion in 3 phases; Phase 2 by Oct 2026, Phase 3 by Mar 2027
- Aerospace & Defense to double revenues in FY27; new facilities and NADCAP approval
- Data center infra order INR45 Cr for FY27; dedicated facility setup for scale-up
- Working capital days reduced to 59; target below 100 days for FY27
- Capex INR500 Cr planned over FY27-FY28; INR35 Cr spent in Q1
- Product division growth driven by aerospace, clean energy; expected to exceed INR1000 Cr by FY30
- Multiple analyst queries on nuclear order execution timelines and capex; management confident on ramp-up
Source: Original filing PDF
—
view on exchange portal
⚡ You're reading this after the fact — subscribers got it instantly
ISA
Indian Stock Alerts
BOT
🚨 MTARTECH — Quarterly Results
Revenue: ₹2,35,800 Cr (+12% YoY)
PAT: ₹19,200 Cr (+17% YoY)
EBITDA margin: 16.8%
Board declared ₹10/share dividend. Jio adds 8M subs.
📎 bseindia.com/xml-data/...
🎧 Audio summary ready
✓✓ 6:47 PM
Instant audio summaries2-min AI concall recap delivered with every earnings alert
20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings
Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically
Instant Telegram alertsResults, board meetings, insider trades — within minutes
Add MTARTECH to your watchlist — all of this, automated.
Sign in with Google14-day Pro trial · No credit card · Cancel anytime
More on Mtar Technologies Limited
Important.
The summary above is generated automatically from Mtar Technologies Limited's own
public regulatory filing under SEBI LODR. Indian Stock Alerts is
not a SEBI-registered Research Analyst or Investment Adviser.
This page is informational, not investment advice, a recommendation to buy
or sell any security, or any opinion about the company's business, governance
or financial health. Always read the original filing before acting and consult
a registered adviser for investment decisions.